Takako Inoue

机构：Osaka International Cancer Institute, Osaka International Cancer Institute · ORCID：0009-0002-8698-0590

发表论文 24 篇 · 总被引 812 次 · h-index 9

代表论文

• Osimertinib after Chemoradiotherapy in Stage III EGFR -Mutated NSCLC (2024 · New England Journal of Medicine · 被引 325)
• Phase III KEYNOTE-789 Study of Pemetrexed and Platinum With or Without Pembrolizumab for Tyrosine Kinase Inhibitor‒Resistant, EGFR –Mutant, Metastatic Nonsquamous Non–Small Cell Lung Cancer (2024 · Journal of Clinical Oncology · 被引 154)
• Pemetrexed and platinum with or without pembrolizumab for tyrosine kinase inhibitor (TKI)-resistant, EGFR -mutant, metastatic nonsquamous NSCLC: Phase 3 KEYNOTE-789 study. (2023 · Journal of Clinical Oncology · 被引 94)
• Analysis of Impurities in Methamphetamine (1983 · Eisei kagaku · 被引 27)
• Osimertinib (osi) after definitive chemoradiotherapy (CRT) in patients (pts) with unresectable stage (stg) III epidermal growth factor receptor-mutated (EGFRm) NSCLC: Primary results of the phase 3 LAURA study. (2024 · Journal of Clinical Oncology · 被引 12)
• Analysis of Methamphetamine in Human Hair by Mass Fragmentography (1984 · Eisei kagaku · 被引 12)